Phathom Pharmaceuticals

OverviewSuggest Edit

Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer.
TypePublic
Founded2018
HQBuffalo Grove, US
Websitephathompharma.com

Latest Updates

Employees (est.) (Sept 2019)16(+34%)
Job Openings3
Share Price (Mar 2020)$25.8

Key People/Management at Phathom Pharmaceuticals

Tadataka Yamada

Tadataka Yamada

Co-founder, Chairman
Azmi Nabulsi

Azmi Nabulsi

Co-founder, Chief Operating Officer
Tom Harris

Tom Harris

Head of Regulatory Affairs
James Topper

James Topper

Director
Joe Hand

Joe Hand

Chief Administrative Officer
Michael Cola

Michael Cola

Director
Show more

Phathom Pharmaceuticals Office Locations

Phathom Pharmaceuticals has an office in Buffalo Grove
Buffalo Grove, US (HQ)
2150 E Lake Cook Rd #800Buffalo
Show all (1)

Phathom Pharmaceuticals Financials and Metrics

Phathom Pharmaceuticals Revenue

USD

Net income (FY, 2019)

(255.1m)

EBIT (FY, 2019)

(106.2m)

Market capitalization (31-Mar-2020)

747.9m

Closing stock price (31-Mar-2020)

25.8

Cash (31-Dec-2019)

243.8m

EV

527.0m
Phathom Pharmaceuticals's current market capitalization is $747.9 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

1.2m6.9m

R&D expense

20.0k20.4m

Operating expense total

2.5m27.3m

EBIT

(1.2m)(106.2m)
Quarterly
USDQ3, 2019

General and administrative expense

1.8m

R&D expense

4.5m

Operating expense total

6.3m

EBIT

(6.3m)
Annual
USDFY, 2018FY, 2019

Cash

879.0k243.8m

Prepaid Expenses

11.8m

Current Assets

902.0k255.6m

PP&E

463.0k
Quarterly
USDQ2, 2019Q3, 2019

Cash

82.9m74.5m

Prepaid Expenses

3.2m

Current Assets

84.5m77.7m

PP&E

40.0k
Annual
USDFY, 2018FY, 2019

Net Income

(1.3m)(255.1m)

Depreciation and Amortization

8.0k

Accounts Payable

2.3m

Cash From Operating Activities

(1.0m)(36.5m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019

Net Income

(514.0k)(89.0m)(157.1m)

Depreciation and Amortization

2.0k

Accounts Payable

1.6m

Cash From Operating Activities

(452.0k)(6.0m)(13.1m)
USDY, 2019

EV/EBIT

-5 x

EV/CFO

-14.4 x

Financial Leverage

1.1 x
Show all financial metrics

Phathom Pharmaceuticals Operating Metrics

Oct, 2019

Drugs in Development

1

Phase III Trials Products

1
Show all operating metrics

Phathom Pharmaceuticals Online and Social Media Presence

Embed Graph

Phathom Pharmaceuticals News and Updates

Phathom Pharmaceuticals Rises Almost 30% After $182 Million

Phathom Pharmaceuticals Rises in Debut After $182 Million IPO

Phathom Pharmaceuticals goes public

Menlo Park, California-based Phathom Pharmaceuticals, a biopharmaceutical company focused on treating gastrointestinal diseases, has raised about $181.7 million for its IPO after pricing its over 9.5 million shares at $19 per share. The stock began trading October 25, 2019 on the NASDAQ under the ti…

Phathom Pharmaceuticals Frequently Asked Questions

  • When was Phathom Pharmaceuticals founded?

    Phathom Pharmaceuticals was founded in 2018.

  • Who are Phathom Pharmaceuticals key executives?

    Phathom Pharmaceuticals's key executives are Tadataka Yamada, Azmi Nabulsi and Tom Harris.

  • How many employees does Phathom Pharmaceuticals have?

    Phathom Pharmaceuticals has 16 employees.

  • Who are Phathom Pharmaceuticals competitors?

    Competitors of Phathom Pharmaceuticals include Verrica Pharmaceuticals, SciBac and Complexa.

  • Where is Phathom Pharmaceuticals headquarters?

    Phathom Pharmaceuticals headquarters is located at 2150 E Lake Cook Rd #800Buffalo, Buffalo Grove.

  • Where are Phathom Pharmaceuticals offices?

    Phathom Pharmaceuticals has an office in Buffalo Grove.

  • How many offices does Phathom Pharmaceuticals have?

    Phathom Pharmaceuticals has 1 office.